Collection: Monthly Giving Mystery Boxes
Our Monthly Giving Mystery Boxes make supporting pancreatic cancer research exciting, meaningful, and fun. Each box delivers a surprise—whether it’s a curated digital wallpaper, a special item from our shop, trending viral products, or the premium Big Kahuna experience. Every purchase directly benefits Sky Foundation, a nonprofit dedicated to raising awareness and funding innovative research for pancreatic cancer.
Choose the giving level that fits you best and enjoy the thrill of unboxing something new each month. From small digital surprises to larger collections and premium items, each mystery box carries hope, joy, and impact. By subscribing, you’re not just receiving unique treasures—you’re joining a community determined to shine a light on early detection and help advance the fight against pancreatic cancer.

-
$25 Digital Mystery Box
Regular price $25.00 USDRegular priceUnit price / per -
Viral Product Mystery Box
Regular price $75.00 USDRegular priceUnit price / per -
$100 Mystery Box
Regular price $100.00 USDRegular priceUnit price / per -
$50 Mystery Box
Regular price $50.00 USDRegular priceUnit price / per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...